EvviVax, a unit of Italy-based Takis Biotech, and New York-based Applied DNA Sciences are collaborating on a feline vaccine for SARS-CoV-2 that is based on Takis' COVID-19 vaccine. Though SARS-CoV-2 infections have been confirmed in only 54 domestic cats in the US, Takis CEO Luigi Aurisicchio says vaccinating cats will prevent virus mutations that could be dangerous to people and pets.
Sign up for FBR SmartBrief
Biomedical Research News
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.